[Venous thrombosis and cancer]

Area of Science:

• Oncology
• Hematology
• Thrombosis Research

Background:

• Idiopathic venous thromboembolism (VTE) is linked to a higher incidence of newly diagnosed cancer, particularly colorectal, prostate, pancreas, lung, and ovarian cancers, within 6-12 months post-diagnosis.
• Cancer patients frequently exhibit a hypercoagulable state, evidenced by abnormal routine blood tests in up to 90% and elevated coagulation activation markers.
• The clinical manifestations of this hypercoagulability include thrombosis, hemorrhage, and disseminated intravascular coagulation (DIC).

Purpose of the Study:

• To review the association between idiopathic VTE and the subsequent diagnosis of cancer.
• To discuss the hemostatic abnormalities observed in cancer patients and their clinical implications.
• To evaluate the current understanding of the pathophysiology linking cancer and thrombosis.

Main Methods:

• Literature review of studies investigating the link between idiopathic VTE and cancer diagnosis.
• Analysis of data on hypercoagulable states in cancer patients, including routine blood test abnormalities and specific coagulation markers.
• Examination of the pathophysiology of cancer-associated thrombosis.

Main Results:

• A statistically significant increase in cancer incidence is observed 6-12 months after an idiopathic VTE diagnosis.
• Hypercoagulable states are common in cancer patients, manifesting as bleeding or clotting disorders.
• The complex interplay between tumor cells and host cells contributes to the thrombophilic state in cancer.

Conclusions:

• While an association exists, current evidence does not support extensive cancer screening in all idiopathic VTE patients.
• Cancer-associated thrombosis is a significant risk, yet no reliable biological test currently predicts VTE in these patients.
• Prophylaxis with anticoagulants is recommended in specific clinical situations like surgery or chemotherapy for cancer patients.